Market Overview

Medicrea Announces Record Sales for the First Half of 2018


Continued growth momentum over first half of 2018

New historic invoicing record for the 2nd quarter of 2018: € 8.8

2018 first-half record sales: € 16.9 million, + 15%, and + 22% at
constant exchange rates

Acceleration in the number of patient-specific UNiD ASI™ surgeries:
+50% in the US for HY1 2018

The Medicrea Group (Euronext Growth Paris: FR0004178572 -ALMED),
pioneering the convergence of healthcare IT and next-generation,
outcome-centered spinal device design with UNiD ASI™ (Adaptive Spine
Intelligence) technology, announced today sales for the first half of

Sales for the first half of 2018 amounted to € 16.9 million, up 22% at
constant exchange rates compared to the first half of 2017. Second
quarter sales reached € 8.8 million, a new historic performance
following the previous record of € 8.2 million in the first quarter of

"We have resumed the path of sustained growth, with the expectation that
recent US registrations for two key product families in our development
strategy, the top-loading thoracolumbar fixation system PASS TULIP™ and
our IB3D™ 3D-printed titanium interbody cages, will further contribute
to the turnover from the second half of 2018," stated Denys Sournac,
President and CEO of Medicrea.

The month of June 2018 shows the best performance of the year with:

- Sales for an amount of € 3.4 million, reflecting the resumption of
strong growth from the very beginning of 2018;

- Record number of 116 patient-specific UNiD® Rod surgeries performed
for the month of June, confirming  the adoption of personalized UNID
ASI™ services and implants by a growing number of surgeons. In total,
2,500 UNiD® patient-specific surgeries have been performed since the
launch of this technology associated with service expertise delivered by
the UNiD Lab™.

In the United States, patient-specific UNID® surgeries are reported to
be up + 50% in the first half of 2018 compared to the same period in
2017. The reorganization of the sales force at the end of 2017 aimed at
refocusing efforts on the UNiD ASI™ platform is starting to bear fruit.
The UNiD ASI™ activity represents more than 60% of total sales for the
US subsidiary.

Outside of the United States, sales with international distributors grew
by 40% following the opening of new countries and the resumption of
invoicing in Brazil. The new Belgian subsidiary, Medicrea Belgium, which
was incorporated in February 2018, contributed significantly to the
half-year turnover, as hospitals are now billed directly. In France, the
Company is also continuing its market share gains with a + 3% growth in
sales. Medicrea is now also active on the Australian market with a
distribution subsidiary operating since June that is expected to
represent a significant source of additional revenue in the medium term
given the attractive pricing sustained by the local market for premium

"In 2018, we have started to see strong growth in the use of our UNiD
ASI™ preoperative planning services and patient-specific implants, which
confirms that surgeons are interested in this technology and moreover
the relevance of our strategic positioning. We believe that this fully
personalized approach to treating spinal pathologies will become the
standard of care over the coming years as it improves patient outcomes
while reducing costs to the healthcare system," stated Denys Sournac,
President and CEO of Medicrea.

"In May of 2018, the Company achieved FDA 510(k) clearance for its
3D-printed patient-specific interbody devices. With this world-first
clearance, Medicrea is able to digitally plan, manufacture in-house and
supply a 3D-printed device in the United States that has been optimized
to follow each patient's unique spinal anatomy using the Company's
proprietary AI-driven UNiD technology," Mr. Sournac continued.

"We are confident in pursuing this growth throughout the second half of
the year, particularly in the United States, by deploying new services
and products for the personalized treatment of spinal pathologies and
should be on track to be EBITDA positive during 2018," Mr. Sournac

Next publication: Results for the First Half of 2018: Tuesday,
September 18, 2018, after-market.

About Medicrea (

Through the lens of predictive medicine, Medicrea leverages its
proprietary software analysis tools with big data and machine learning
technologies supported by an expansive collection of clinical and
scientific data. The Company is well-placed to streamline the efficiency
of spinal care, reduce procedural complications and limit time spent in
the operating room.

Operating in a $10 billion marketplace, Medicrea is a Small and Medium
sized Enterprise (SME) with 185 employees worldwide, which includes 50
who are based in the U.S. The Company has an ultra-modern manufacturing
facility in Lyon, France housing the development and production of
3D-printed titanium patient-specific implants.

For further information, please visit:

Connect with Medicrea:


Medicrea is listed on

EURONEXT Growth Paris

ISIN: FR 0004178572

Ticker: ALMED


View Comments and Join the Discussion!